AI-Discovered BRP Peptide Cuts Appetite Through a Different Brain Circuit
Stanford Medicine researchers have identified a naturally occurring peptide, BRP, that sharply reduced food intake and promoted fat loss in animal models while appearing to avoid several of the gastrointestinal and muscle-related effects that complicate current obesity drugs. In lean mice and minipigs, the peptide reduced eating by as much as 50% in the hour after dosing. In obese mice given daily injections for 14 days, body weight fell by an average of 3 grams while untreated controls gained about 3 grams.
The work matters because it points to a path beyond the one dominated by semaglutide and other GLP-1 receptor agonists. Those agents have transformed obesity treatment, yet they act on receptors distributed across the brain, gut, pancreas, and other tissues, which helps explain why nausea, constipation, and other off-target effects are common. BRP appears to engage a more selective hypothalamic pathway, a narrower route that could, in principle, suppress hunger without the broader digestive consequences seen with incretin-based therapy.
One result stood out immediately: the peptide preserved lean mass while shifting the weight-loss signal toward fat.
Why the Hypothalamus Became the Target
The hypothalamus sits deep in the brain and orchestrates hunger, energy expenditure, body temperature, and other homeostatic functions. A molecule that acts there can influence eating behavior at the command center rather than by changing digestion alone. That distinction is clinically relevant because obesity treatment succeeds or fails not just on the scale, but on whether patients can tolerate the therapy long enough to stay on it.
Semaglutide mimics GLP-1, a hormone that helps regulate blood sugar and satiety. Its broad tissue distribution gives it therapeutic power, but it also creates the adverse-effect burden that has limited acceptance for some patients. BRP emerged from a different biochemical route: it is generated from a larger precursor protein through specific enzymatic cleavage, and the evidence so far suggests it activates distinct populations of brain cells. The result is a peptide that behaves like a metabolic switch, but one wired into a more selective circuit.
That mechanism could prove important if future human studies reproduce the animal data. A drug that reduces appetite without substantially slowing the gut or causing notable muscle loss would address two of the most persistent barriers to chronic obesity care.
Artificial Intelligence Narrowed 20,000 Human Genes to a Workable Search
The discovery began with a computational problem. Human biology produces an enormous number of protein fragments, but only a small fraction have hormonal activity. Traditional peptide discovery relies on labor-intensive tissue extraction and mass spectrometry, a process ill-suited to sorting through such a vast molecular field.
Investigators built an algorithm called Peptide Predictor and used it to scan roughly 20,000 human genes for sequences likely to be cut by prohormone convertase 1/3, an enzyme linked to obesity and known to generate hormones such as GLP-1. The search was then narrowed to proteins expected to be secreted outside cells and to those containing at least four potential cleavage sites. Those filters reduced the candidate pool to 373 prohormones and yielded 2,683 predicted peptides.
From that list, 100 peptides were tested in cultured nerve cells. GLP-1 increased neuronal activity to three times control levels, but one previously unrecognized 12-amino-acid peptide drove neuronal activity to ten times baseline. The peptide was named BRP, short for BRINP2-related-peptide, after the protein from which it originates. That signal was strong enough to justify animal testing, and the subsequent in vivo results delivered the clearest proof that the computational approach had found something biologically meaningful.
Animal Data Showed Weight Loss, Fat Loss, and Better Glucose Handling
In lean mice and minipigs, BRP was injected into muscle before feeding, and food intake dropped by up to 50% over the next hour. In obese mice treated daily for 14 days, the peptide reversed weight gain rather than merely slowing it. Nearly all of the lost weight came from body fat, not muscle, which is a critical distinction in obesity medicine because loss of lean tissue can impair strength, mobility, and metabolic health.
The treated mice also showed improved glucose and insulin tolerance. Those endpoints suggest that BRP may do more than blunt appetite; it may also improve how the body manages circulating sugar and responds to insulin. For clinicians, that combination is attractive because obesity rarely travels alone. Insulin resistance, fatty liver disease, and cardiometabolic risk often shadow excess adiposity, so a drug that influences both intake and metabolic handling would be especially valuable.
The signaling pattern also appears different from GLP-1 agonism. BRP activated distinct neuronal and metabolic pathways rather than simply duplicating semaglutide’s biology. In practical terms, that means the peptide may reach a similar endpoint through a more selective route, which could matter for tolerability.
Digestive Tolerance Looked Better in the Short Animal Window
The investigators monitored movement, water consumption, anxiety-related behavior, and fecal output in treated mice and pigs. They found no significant differences versus controls. The lack of a fecal-output change is particularly notable because constipation remains one of the more common reasons patients struggle with GLP-1-based therapy.
Animal models cannot answer the full question of nausea, and they cannot substitute for human reporting of satiety, abdominal discomfort, or treatment acceptance. Still, the absence of obvious digestive disruption in the preclinical setting gives BRP a different safety profile on paper than the one seen with current incretin therapies. If that pattern holds in people, it could reshape how obesity medications are selected for patients who cannot tolerate GLP-1 drugs or who lose too much lean mass while taking them.
Human Trials Will Decide Whether the Signal Becomes a Drug
BRP remains an early-stage candidate. The next steps are straightforward in concept and difficult in execution: identify the receptor or receptors that recognize the peptide, determine how long it remains active in the body, and establish whether a longer-lasting formulation can be developed without losing potency. Peptides are often broken down quickly, so dosing convenience may become as important as biological effect if the molecule reaches clinical testing.
The central unknown is translation from animals to humans. Appetite regulation is conserved across species, but obesity treatment fails often enough in late-stage development to warrant restraint. Safety, dose selection, durability, and side-effect burden all need direct testing in people before BRP can be considered a realistic therapeutic option.
Katrin Svensson, the senior author, has already moved toward translation with a company focused on advancing the peptide toward clinical trials. The study’s patents and commercial ties make the disclosure straightforward: the biology is compelling, but the human evidence does not yet exist. For now, BRP is best understood as a carefully mapped preclinical candidate — one discovered by AI, validated in animals, and still waiting for the first proof that its appetite-suppressing effect can survive the trip into human obesity medicine.